Abstract
ABSTRACTV3-glycan-targeting broadly neutralizing antibodies (bNAbs) are a focus of HIV-1 vaccine development. Understanding the viral dynamics that stimulate the development of these antibodies can provide insights for immunogen design. We used a deep-sequencing approach, together with neutralization phenotyping, to investigate the rate and complexity of escape from V3-glycan-directed bNAbs compared to overlapping early strain-specific neutralizing antibody (ssNAb) responses to the V3/C3 region in donor CAP177. Escape from the ssNAb response occurred rapidly via an N334-to-N332 glycan switch, which took just 7.5 weeks to reach >50% frequency. In contrast, escape from the bNAbs was mediated via multiple pathways and took longer, with escape first occurring through an increase in V1 loop length, which took 46 weeks to reach 50% frequency, followed by an N332-to-N334 reversion, which took 66 weeks. Importantly, bNAb escape was incomplete, with contemporaneous neutralization observed up to 3 years postinfection. Both the ssNAb response and the bNAb response were modulated by the presence/absence of the N332 glycan, indicating an overlap between the two epitopes. Thus, selective pressure by ssNAbs to maintain the N332 glycan may have constrained the bNAb escape pathway. This slower and incomplete viral escape resulted in prolonged exposure of the bNAb epitope, which may in turn have aided the maturation of the bNAb lineage.IMPORTANCE The development of an HIV-1 vaccine is of paramount importance, and broadly neutralizing antibodies are likely to be a key component of a protective vaccine. The V3-glycan-targeting bNAb responses are among the most promising vaccine targets, as they are commonly elicited during infection. Understanding the interplay between viral evolution and the development of these antibodies provides insights that may guide immunogen design. Our work contrasted the dynamics of the early strain-specific antibodies and the later broadly neutralizing responses to a common Env target (V3C3), showing slower and more complex escape from bNAbs. Constrained bNAb escape, together with evidence of contemporaneous autologous virus neutralization, supports the proposal that prolonged exposure of the bNAb epitope enabled the maturation of the bNAb lineage.
Highlights
IMPORTANCE The development of an HIV-1 vaccine is of paramount importance, and broadly neutralizing antibodies are likely to be a key component of a protective vaccine
Most V3-glycan Broadly neutralizing antibodies (bNAbs) are highly dependent on the N332 glycan [9, 12, 19,20,21], this varies within bNAb lineages [6, 21, 22], and loss of this glycan has been associated with viral escape [6, 13, 16, 20, 21, 23]
In order to evaluate virus-antibody dynamics relevant to the V3-glycan class of bNAbs, we studied an HIV-1-infected individual, CAP177, who developed an strain-specific neutralizing antibody (ssNAb) response to the V3/C3 region at 19 weeks postinfection [31], as well as a V3-glycan bNAb response, which first emerged at approximately 1 year postinfection and matured gradually to reach 52% breadth by 3 years postinfection [16, 32]
Summary
IMPORTANCE The development of an HIV-1 vaccine is of paramount importance, and broadly neutralizing antibodies are likely to be a key component of a protective vaccine. The V3-glycan targeting bNAb responses may be easiest to elicit via vaccination, because they are among the most common and potent bNAb responses in infected individuals [7,8,9,10], can develop relatively early in infection, and do not always require extensive somatic hypermutation [4, 11, 12]. These bNAbs have the highest expected therapeutic effectiveness [10] and have been shown to suppress viremia in passive immunization studies [13]. An increase in V1 loop length, and its glycosylation content, can mediate escape from this class of bNAbs [5, 6, 24, 26, 27]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.